Atara Biotherap (NQ: ATRA )

17.91 USD +0.93 (+5.48%)

Streaming Delayed Price Updated: 11:20 AM EST, Dec 7, 2021 Add to My Watchlist

Price and Volume

Volume	169,076
Open	17.00
Bid (Size)	17.86 (3)
Ask (Size)	17.93 (3)
Prev. Close	16.98
Today's Range	17.00 - 18.09
52wk Range	11.81 - 28.20
Shares Outstanding	88,417,386
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 03, 2021

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and...

European Medicines Agency (EMA) Validates Atara Biotherapeutics' Marketing Authorization Application for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferat

November 30, 2021

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and...

Performance

YTD	-8.81%	-8.81%
1 Month	+1.53%	+1.53%
3 Month	+16.98%	+16.98%
6 Month	+27.38%	+27.38%
1 Year	-31.72%	-31.72%

More News

Atara Biotherapeutics to Participate at Three Upcoming Investor Conferences

November 08, 2021

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 05, 2021

Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of Tab-cel® Pivotal Phase 3 (ALLELE) Data

November 04, 2021

Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress

November 04, 2021

Atara Biotherapeutics to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021

October 28, 2021

Atara Biotherapeutics Presents New Magnetization Transfer Ratio Imaging Data and Two-Year Clinical Data from the Open Label Extension of ATA188 for Progressive Multiple Sclerosis at ECTRIMS 2021

October 13, 2021

How Bad Are Atara Biotherapeutics's Earnings? | Return On Capital Employed

November 05, 2021

Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)

October 04, 2021

First Week of June 2022 Options Trading For Atara Biotherapeutics (ATRA)

October 15, 2021

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.